Premium
Reactivity of Anti‐Asialo GM 1 Serum With Tumoricidal and Non‐Tumoricidal Mouse Macrophages
Author(s) -
Wiltrout Robert H.,
Santoni Angela,
Peterson Erik S.,
Knott Denise C.,
Overton W. Roy,
Herberman Ronald B.,
Holden Howard T.
Publication year - 1985
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.37.5.597
Subject(s) - in vitro , in vivo , reactivity (psychology) , chemistry , biology , biochemistry , medicine , pathology , alternative medicine , microbiology and biotechnology
All peritoneal macrophage (pMφ) populations studied exhibited some binding of the anti‐asGM 1 serum as assessed by flow cytometry. The levels of reactivity varied quantitatively among populations, depending on the combination of eliciting and activating agents employed prior to the harvest of pMφ. Resident pMφ contained a very small percentage (4%) of cells that were strongly asGM 1 +. Any treatment of these cells that induced them to become stimulated or activated increased the percentage of highly asGM 1 + cells. Treatments that enhanced anti‐asGMi binding including eliciting pMφ with proteose peptone (16% asGM 1 +) or Brewer's thioglycollate medium (66% asGM 1 + ), treatment with the activating biological response modifiers (BRMs) MVE‐2 (12% asGM 1 +) and P acnes (18% asGM 1 +), or treatment with both peptone + MVE‐2 (37% asGM 1 +) or peptone + poly IC/LC (33%). Increased expression of anti‐asGM 1 was accompanied by some increase in the reactivity of the various pMφ populations to treatment with anti‐asGMj serum. This conclusion was based on the reduced viabilities of cells treated with both an eliciting agent and an activating agent prior to in vitro treatment with anti‐asGM 1 + C, as well as by reductions in cytolytic activity of pMφ elicited with peptone and activated by MVE‐2, following anti‐asGM 1 treatment in vitro or administration in vivo. Conversely, the cytolytic activity of resident pMφ activated in vivo by MVE‐2 or heat‐killed P acnes, agents that induced relatively small increases in the percentage of asGM 1 φ cells, was resistant to the effects of in vivo and/or in vitro treatment with doses of anti‐asGM 1 serum that inhibit NK activity. These results indicate that stimulation of pM φ by eliciting or activating agents can increase the level of expression of asGM 1 This increased expression of asGM 1 may be a useful marker for some aspects of macrophage heterogeneity, but increased expression is not necessarily directly related to expression of tumor‐ icidal activity. In fact, the results of this study demonstrate that anti‐asGM 1 serum can be used for specific depletion of NK activity in vivo in normal mice and in mice treated with at least some BRMs. However, the results also demonstrate that the use of eliciting agents, particularly thioglycollate, or eliciting agents in conjunction with activating agents can cause pMφ to become reactive with anti‐asGM 1 serum.